{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:30:48Z","timestamp":1786465848883,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["22K06732"],"award-info":[{"award-number":["22K06732"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SHOWA Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40262-026-01662-0","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:48:13Z","timestamp":1782233293000},"page":"1229-1241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"65","author":[{"given":"Kosuke","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Otoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Masuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuya","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuu","family":"Shimozuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Uchikoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoka","family":"Hayano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Hanano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Murase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Mitomori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8135-5679","authenticated-orcid":false,"given":"Yukio","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1575-6690","authenticated-orcid":false,"given":"Ken-ichi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"3","key":"1662_CR1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.23131","volume":"122","author":"J Matsui","year":"2008","unstructured":"Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3):664\u201371.","journal-title":"Int J Cancer"},{"issue":"17","key":"1662_CR2","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","volume":"14","author":"J Matsui","year":"2008","unstructured":"Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14(17):5459\u201365.","journal-title":"Clin Cancer Res"},{"key":"1662_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.","journal-title":"Vasc Cell"},{"key":"1662_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/638747","volume":"2014","author":"O Tohyama","year":"2014","unstructured":"Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, et al. Antitumor activity of Lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.","journal-title":"J Thyroid Res"},{"issue":"10126","key":"1662_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"2","key":"1662_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374.","journal-title":"J Hepatol"},{"issue":"6","key":"1662_CR7","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1158\/1078-0432.CCR-15-1354","volume":"22","author":"M Ikeda","year":"2016","unstructured":"Ikeda M, Okusaka T, Mitsunaga S, Ueno H, Tamai T, Suzuki T, et al. Safety and Pharmacokinetics of Lenvatinib in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2016;22(6):1385\u201394.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1662_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40261-014-0217-y","volume":"34","author":"RC Shumaker","year":"2014","unstructured":"Shumaker RC, Aluri J, Fan J, Martinez G, Thompson GA, Ren M. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Investig. 2014;34(9):651\u20139.","journal-title":"Clin Drug Investig"},{"issue":"8","key":"1662_CR9","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1124\/dmd.114.058073","volume":"42","author":"K Inoue","year":"2014","unstructured":"Inoue K, Mizuo H, Kawaguchi S, Fukuda K, Kusano K, Yoshimura T. Oxidative metabolic pathway of Lenvatinib mediated by aldehyde oxidase. Drug Metab Dispos. 2014;42(8):1326\u201333.","journal-title":"Drug Metab Dispos"},{"key":"1662_CR10","unstructured":"US Food and Drug Administration. Drug Information: Lenvatinib. [cited 27 November 2025]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/206947s033lbl.pdf"},{"issue":"8","key":"1662_CR11","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-10-2638","volume":"17","author":"K Yamada","year":"2011","unstructured":"Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, et al. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res. 2011;17(8):2528\u201337.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1662_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/jcph.398","volume":"55","author":"R Shumaker","year":"2015","unstructured":"Shumaker R, Aluri J, Fan J, Martinez G, Pentikis H, Ren M. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration. J Clin Pharmacol. 2015;55(3):317\u201327.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1662_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550\u20138.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1662_CR14","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/jcph.917","volume":"57","author":"T Tamai","year":"2017","unstructured":"Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K, et al. Dose finding of Lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses. J Clin Pharmacol. 2017;57(9):1138\u201347.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1662_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s12890-022-02249-8","volume":"22","author":"Y Nio","year":"2022","unstructured":"Nio Y, Ishida H, Matsumoto N, Kusumoto S, Kubota Y, Tsunoda T, et al. Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. BMC Pulm Med. 2022;22(1):454.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"1662_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.surge.2019.09.002","volume":"18","author":"M Deng","year":"2020","unstructured":"Deng M, Ng SWY, Cheung ST, Chong CCN. Clinical application of Albumin-Bilirubin (ALBI) score: the current status. Surgeon. 2020;18(3):178\u201386.","journal-title":"Surgeon"},{"issue":"3","key":"1662_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Br\u00fa C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329\u201338.","journal-title":"Semin Liver Dis"},{"key":"1662_CR18","unstructured":"dbSNP. National Center for Biotechnology Information [Accessed 27 November 2025] Available from: https:\/\/www.ncbi.nlm.nih.gov\/snp\/"},{"key":"1662_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041005","author":"LB Jeng","year":"2023","unstructured":"Jeng LB, Chan WL, Teng CF. Prognostic significance of serum Albumin level and Albumin-based mono- and combination biomarkers in patients with Hepatocellular Carcinoma. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15041005.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1662_CR20","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","volume":"77","author":"AM Allen","year":"2022","unstructured":"Allen AM, Therneau TM, Ahmed OT, Gidener T, Mara KC, Larson JJ, et al. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. J Hepatol. 2022;77(5):1237\u201345.","journal-title":"J Hepatol"},{"issue":"1","key":"1662_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jphs.2021.08.011","volume":"148","author":"H Okubo","year":"2022","unstructured":"Okubo H, Ando H, Ishizuka K, Morishige JI, Ikejima K, Shiina S, et al. Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma. J Pharmacol Sci. 2022;148(1):6\u201313.","journal-title":"J Pharmacol Sci"},{"issue":"8","key":"1662_CR22","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00228-020-02879-z","volume":"76","author":"J Li","year":"2020","unstructured":"Li J, Wang X, Ning C, Wang Z, Wang Y, Zheng M, et al. Influences of ABC transporter and CYP3A4\/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects. Eur J Clin Pharmacol. 2020;76(8):1125\u201333.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1662_CR23","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1038\/s41598-019-41820-y","volume":"9","author":"T Ozeki","year":"2019","unstructured":"Ozeki T, Nagahama M, Fujita K, Suzuki A, Sugino K, Ito K, et al. Influence of CYP3A4\/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019;9(1):5404.","journal-title":"Sci Rep"},{"key":"1662_CR24","doi-asserted-by":"publisher","unstructured":"Matsumoto N, Oishi A, Yoshino S, Masuo Y, Kubota Y, Ishida H, Shimada K, Kato Y, Fujita KI. ABCC4 polymorphism indirectly reduces systemic exposure\nto a capecitabine metabolite 5\u2032-deoxy-5-fluorouridine in Japanese subjects. British J Clin Pharmacol. 2025;91(11):3092\u2013103. https:\/\/doi.org\/10.1002\/bcp.70152.","DOI":"10.1002\/bcp.70152"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01662-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01662-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01662-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:17:07Z","timestamp":1786461427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01662-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1662"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01662-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Open Access funding provided by SHOWA Medical University. This study was supported in part by Grant-in-Aid for Scientific Research (C) [22K06732 to K.F.] from the Japan Society for the Promotion of Science (JSPS).","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared no conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data generated or analyzed during this study are included in this published article and in the Online Resource.","order":3,"name":"Ethics","label":"Data Availability Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted following the ethical standards outlined in the Declaration of Helsinki. The Institutional Review Board of Showa Medical University approved the study protocol (approval number, G305; date, April 16, 2020).","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for the use of peripheral blood samples and medical information for research purposes was obtained from all patients.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients signed informed consent regarding publishing their data.","order":6,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kosuke Suzuki, Yumi Otoyama, Natsumi Matsumoto, Remi Murase, Masashi Sakaki, Yukio Kato, and Ken-ichi Fujita wrote the manuscript; Kosuke Suzuki, Yumi Otoyama, Yukio Kato, Hitoshi Yoshida, and Ken-ichi Fujita designed the study; Kosuke Suzuki, Yumi Otoyama, Natsumi Matsumoto, Remi Murase, Yoko Nakajima, Ikuya Sugiura, Takahiro Fuzi, Erika Nomura, Yuki Ichikawa, Yuu Shimozuma, Manabu Uchikoshi, Momoka Hayano, Mayuko Hanano, Chika Mitomori, Masashi Sakaki, Yukio Kato, Hitoshi Yoshida, and Ken-ichi Fujita performed the experiments; Kosuke Suzuki, Yumi Otoyama, Natsumi Matsumoto, Yusuke Masuo, Momoka Hayano, Mayuko Hanano, Remi Murase, Yukio Kato, and Ken-ichi Fujita analyzed the data.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}